Premium
Cardiovascular morbidity and mortality in patients with spondyloarthritis: A meta‐analysis
Author(s) -
Kim Ji Hyoun,
Choi In Ah
Publication year - 2021
Publication title -
international journal of rheumatic diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 41
eISSN - 1756-185X
pISSN - 1756-1841
DOI - 10.1111/1756-185x.13970
Subject(s) - medicine , meta analysis , population , stroke (engine) , psoriatic arthritis , relative risk , myocardial infarction , ankylosing spondylitis , medline , confidence interval , arthritis , environmental health , mechanical engineering , political science , law , engineering
Abstract Aim Cardiovascular (CV) risk and mortality associated with spondyloarthritis (SpA) remain controversial. Herein, we performed a meta‐analysis of the latest large‐scale population‐based studies to demonstrate the elevated risk of CV disease and mortality in patients with SpA than in the general population. Methods MEDLINE and EMBASE databases were searched systematically for population‐based studies published between January 1997 and September 2019. Additional manual literature searches were also performed. All searches and data collection were performed independently by 2 reviewers. We calculated the risks of myocardial infarction (MI), stroke, and all‐cause mortality in a meta‐analysis and determined the risk ratios (RR) using the Mantel–Haenszel method. Results Among the 641 identified articles, 16 articles involving 18 cases met the inclusion criteria for our meta‐analysis; these included 12 cases of ankylosing spondylitis, five cases of psoriatic arthritis, and 1 case of undifferentiated SpA. Our meta‐analysis revealed a significantly high risk of MI (RR: 1.52; 95% CI: 1.29‐1.80) and stroke (RR: 1.21; 95% CI: 1.0‐1.47) in patients with SpA than in the general population. However, this increased risk was not significant in terms of all‐cause mortality (RR: 1.23; 95% CI: 0.96‐1.57). Conclusions Our meta‐analysis demonstrated that patients with SpA have a significantly increased risks of MI and stroke, but without a significant increase in the all‐cause mortality, than that in the general population. The higher risk of CV in patients with SpA than that in the general population indicates the need for strict risk factor correction and disease management.